August 2021: Treatment of psoriasis associated with nivolumab

Affiliations

Editorial

Brett Sloan. J Am Acad Dermatol. 2021 Aug.

. 2021 Aug;85(2):317.

doi: 10.1016/j.jaad.2021.05.034. Epub 2021 May 27.

¹ University of Connecticut School of Medicine, Farmington, Connecticut. Electronic address: brettsloanjaad@gmail.com.

No abstract available

Conflict of interest statement

Conflicts of interest None disclosed.

Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma.
Glinos GD, Fisher WS, Morr CS, Seminario-Vidal L. Glinos GD, et al. JAAD Case Rep. 2021 Mar 27;11:74-77. doi: 10.1016/j.jdcr.2021.03.029. eCollection 2021 May. JAAD Case Rep. 2021. PMID: 33948461 Free PMC article. No abstract available.
Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series.
Mayor Ibarguren A, Enrique EA, Diana PL, Ana C, Pedro HP. Mayor Ibarguren A, et al. JAAD Case Rep. 2021 Mar 13;11:84-89. doi: 10.1016/j.jdcr.2021.03.015. eCollection 2021 May. JAAD Case Rep. 2021. PMID: 33948464 Free PMC article. No abstract available.